Bionano Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>BG</div>
BNGO -- USA Stock  

USD 8.05  1.75  17.86%

The upcoming quarterly report is expected on the 9th of March 2021. The stock is still going through an active upward rally. Bionano Genomics Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.30. Current Ratio is expected to rise to 1.76 this year, although the value of Average Assets will most likely fall to about 26.6 M. As many of us are excited about healthcare space, it is fair to outline Bionano Genomics as a unique alternative. Let's inspect the possibilities of Bionano Genomics maintaining its debt level in February.
Published over two weeks ago
View all stories for Bionano Genomics | View All Stories
Should I hold on to my Bionano (NASDAQ:BNGO) position?
Bionano Genomics currently holds 16.01 M in liabilities with Debt to Equity (D/E) ratio of 1.09, which is about average as compared to similar companies. This firm has a current ratio of 1.16, suggesting that it is in a questionable position to pay out its financial obligations when due.
Bionano Genomics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Bionano Genomics, including all of Bionano Genomics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Bionano Genomics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Bionano Genomics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Bionano Total Debt

Bionano Genomics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Bionano Genomics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Bionano Genomics balance sheet include debt obligations and money owed to different Bionano Genomics vendors, workers, and loan providers. Below is the chart of Bionano main long-term debt accounts currently reported on its balance sheet.
You can use Bionano Genomics financial leverage analysis tool to get a better grip on understanding its financial position

How important is Bionano Genomics's Liquidity

Bionano Genomics financial leverage refers to using borrowed capital as a funding source to finance Bionano Genomics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bionano Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bionano Genomics's total debt and its cash.

Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bionano insider trading alert for grant of stock option (right to buy) by Chaubey Alka, Chief Medical Officer, on 11th of October 2020. This event was filed by Bionano Genomics Inc with SEC on 2020-09-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Bionano Genomics Indicators

The latest price rise of Bionano Genomics could raise concerns from institutional investors as the firm it trading at a share price of 3.08 on very low momentum in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 12.84. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Bionano Genomics partners.

Liabilities Breakdown

Total Liabilities26.99 Million
Current Liabilities24.2 Million
Long-Term Liabilities209,676

Are Bionano Genomics technical ratios showing a throwback?

Total risk alpha is down to 1.56. It may entail a possible volatility slide. Bionano Genomics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Bionano Genomics independently to ensure intended market timing strategies are aligned with expectations about Bionano Genomics volatility.

Whereas some firms under the diagnostics & research industry are still a bit expensive, Bionano Genomics may offer a potential longer-term growth to institutional investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Bionano as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Bionano Genomics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com